BPC-157 Research Peptide Guide 2026 — Molecular Profile, Mechanism & Verification

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a protective protein identified in human gastric juice. Over three decades of preclinical literature — a PubMed search now returns more than one hundred peer-reviewed publications — have made it one of the most frequently referenced compounds in cytoprotection, angiogenesis, and tissue-repair research models. For qualified laboratory researchers, that volume of published work is precisely why source verification matters: a compound this widely studied is also widely synthesized, and synthesis quality varies across suppliers.

This guide covers the molecular profile of BPC-157, the receptor and signaling pathways described in the preclinical literature, a survey of published PubMed studies with citation years, common in-vitro research applications, and the documentation a researcher should expect to accompany a research-grade lot.

For in-vitro and preclinical laboratory research use only. Not for human consumption.

Section 1 — Molecular Profile

• Compound name: BPC-157 (Body Protection Compound-157)
• Peptide class: Synthetic pentadecapeptide (15 amino acids)
• Amino acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
• CAS number (free base): 137525-51-0
• CAS number (acetate salt): 1628202-19-6
• Molecular formula: C₆₂H₉₈N₁₆O₂₂
• Molecular weight: ≈ 1419.5 g/mol
• Physical form: Lyophilized white powder
• Origin: Partial sequence corresponding to a cytoprotective protein described in gastric juice

BPC-157 is notable among research peptides for its reported stability. Unlike many peptides that degrade rapidly in aqueous or acidic conditions, the published characterization work describes BPC-157 as resistant to hydrolysis in gastric-juice-like environments, which is one reason it has been used extensively as a model peptide in cytoprotection studies. A 2022 Fourier-transform infrared spectroscopy study (PMC9775416) examined structural characteristics associated with the peptide in vascular tissue models, adding instrumental data to the earlier sequence-level characterization.

Because BPC-157 is a relatively short, unmodified peptide, identity confirmation by mass spectrometry against the expected ≈1419.5 g/mol mass is a straightforward but essential verification step. Sequence truncation or incomplete synthesis produces mass shifts that HPLC purity alone will not reveal.

Section 2 — Mechanism (Pathway-Level Description)

The preclinical literature describes BPC-157 as interacting with several overlapping signaling pathways. These descriptions reflect findings in animal and cell-based research models and are presented here strictly as mechanistic research context.

BPC-157 has been studied for its apparent modulation of the VEGFR2–Akt–eNOS signaling axis, a pathway central to endothelial cell behavior and the formation of new microvasculature in research models. In tendon-derived fibroblast cultures, the peptide has been studied for effects on the FAK–paxillin pathway, which governs cell adhesion and migration. Across multiple models, investigators have described interaction with the nitric oxide (NO) system, including modulation of nitric oxide synthase activity.

Additional preclinical work has examined BPC-157 in the context of growth-hormone-receptor expression in fibroblasts and modulation of inflammatory cytokine profiles in injury models. Reviews have also proposed involvement in what the authors term the brain–gut and gut–brain axis, describing signaling relationships observed in rodent systems.

None of these pathway descriptions constitute evidence of any outcome in humans. They are mechanistic hypotheses and observations drawn from in-vitro and animal research, and they remain the subject of ongoing investigation.

Section 3 — Preclinical Research Data

The BPC-157 preclinical record is broad but almost entirely non-clinical. A 2025 systematic review in orthopaedic sports medicine (Vasireddi et al.) identified 36 studies spanning 1993 to 2024, of which 35 were preclinical and only one involved human subjects — an important framing for any researcher evaluating the compound.

Key themes in the preclinical literature include:

Angiogenesis modeling. Immunohistochemical work using VEGF, CD34, and FVIII markers in muscle and tendon healing models described modulated angiogenesis in BPC-157-treated animals (Sikirić and colleagues). This line of research is frequently cited as the mechanistic basis for the compound’s use as a tool in vascular and repair studies.

Cytoprotection. The earliest characterization work positioned BPC-157 as a stable gastric pentadecapeptide with cytoprotective activity in gastrointestinal research models, establishing the framework later extended to other tissue systems.

Vascular pathway research. More recent preclinical studies have examined BPC-157 in vascular-occlusion models, describing apparent activation of alternative vascular routing when primary vessels were experimentally compromised.

It bears repeating that these are findings in controlled research systems. As of 2026, the published record documents no completed controlled human efficacy trials and no established human safety dataset.

Section 4 — Published Literature (Selected PubMed Citations)

The following are real, published entries a researcher can locate through PubMed or PMC. Years are provided for reference.

• Sikirić P. et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol (2010). PubMed 20388964.
• Sikirić P. et al. Stable gastric pentadecapeptide BPC 157 and the central nervous system. Current Neuropharmacology (2016) — review of gut–brain signaling context.
• Stable Gastric Pentadecapeptide BPC 157 May Recover Brain–Gut Axis and Gut–Brain Axis Function. Pharmaceuticals / PMC10224484 (2023).
• Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157. PMC9775416 (2022).
• Vasireddi N., Hahamyan H., Salata M.J., et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025) — systematic review identifying 36 studies, 1993–2024.
• Sikirić P. et al. Multifunctionality of the BPC 157 peptide and associated 2025 review/commentary series in Pharmaceuticals (Basel) (2025), addressing angiogenesis and nitric-oxide-system modulation.

Researchers should consult the primary sources directly rather than relying on secondary summaries, and should note the strong predominance of preclinical over clinical evidence throughout this body of work.

Section 5 — Research Applications (In-Vitro Use Cases)

Within laboratory settings, BPC-157 is commonly used as a reference or tool compound in the following in-vitro and preclinical contexts:

• Endothelial and angiogenesis assays — as a study compound in tube-formation, migration, and VEGFR2-pathway investigations.
• Fibroblast migration and adhesion studies — examining FAK–paxillin-associated cell behavior in culture.
• Cytoprotection models — as a comparative agent in cell-stress and barrier-integrity experiments.
• Nitric-oxide-system research — investigating NO-synthase-associated signaling in cell and tissue models.

In each case the compound functions as an experimental input in a controlled research design. Reproducibility in these applications depends directly on lot purity and confirmed identity — which is where documentation becomes the deciding variable.

Section 6 — How to Evaluate a Source

For a compound as widely synthesized as BPC-157, the documentation standard should be non-negotiable. A researcher evaluating a supplier should confirm the following before sourcing a lot.

The testing laboratory is named. “Third-party tested” means nothing without a named, accountable laboratory. Look for an ISO 17025 accredited laboratory or equivalent recognized accreditation.

Identity is confirmed by mass spectrometry. For a 15-residue peptide, LC-MS confirmation against the expected ≈1419.5 g/mol mass is the minimum identity standard. HPLC purity confirms that a peak elutes cleanly; it does not confirm the molecular identity of what eluted.

Purity is reported by HPLC with a chromatogram. Research-grade BPC-157 should report high chromatographic purity with a clean primary peak. A numeric purity figure without a visible chromatogram is an incomplete result.

The COA is lot-specific. The batch number on the vial should match the batch number on the certificate of analysis. A COA dated before the lot production date, or one that cannot be traced to a specific order, is not lot-specific documentation.

The result is independently verifiable. If confirming a COA requires contacting the vendor, the verification is vendor-controlled. Accredited laboratories such as ILS Laboratories provide QR-linked COAs verifiable through their own portal, and community platforms such as Janoshik make batch results independently searchable.

Endotoxin and heavy-metal data are present. For cell-biology applications, endotoxin (LAL method) and ICP-MS heavy-metal screening remove two meaningful experimental confounds. Purity and identity alone are incomplete for sensitive in-vitro systems.

On pricing: the current research market for BPC-157 spans a wide range, and higher price does not reliably indicate better verification. The variable that matters is analytical methodology and laboratory accreditation, not the number on the listing.

Section 7 — PYXAX Verification Standard

PYXAX supplies BPC-157 as a lyophilized research compound with independent third-party verification before listing.

Testing — accredited independent laboratories (ISO 17025):

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP 85-style LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number. The batch number on the vial matches the batch number on the COA in the PYXAX COA Library, and researchers can confirm this independently before ordering.

Community verification. Select lots are submitted to Janoshik Analytical for community verification, with results publicly searchable by batch number — no vendor contact required.

Founding-batch transparency. Initial founding batches were verified by Krause Analytical (accredited US laboratory). Ongoing production uses a network of accredited independent laboratories for all lots.

View PYXAX BPC-157 →
View COA Library →
Read The PYXAX Standard →

Additional research compounds and lot COAs are available at pyxax.com/shop/, with the full document archive at pyxax.com/coa-library/ and verification methodology at pyxax.com/standard/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.